Who
Fortunato R. Rocca
Director
Company insider
Files Form 4 as: Director, Interpace Biosciences; President and CEO, Exagen.
In numbers
- Trades disclosed
- 9
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 18 Sep 2019
- Last trade
- 20 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Aug 2026filed 20 Aug 2026 | Interpace Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —69,252 at $0.00 | filing |
| 20 Aug 2026filed 20 Aug 2026 | Interpace Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —69,252 at $0.00 | filing |
| 1 Mar 2022filed 2 Mar 2022 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code F | $31K4,322 at $7.12 | filing |
| 4 Feb 2022filed 8 Feb 2022 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 23 Feb 2021filed 25 Feb 2021 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 23 Feb 2021filed 25 Feb 2021 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 9 Jul 2020filed 10 Jul 2020 | Interpace Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
| 9 Jan 2020filed 9 Jan 2020 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —155,000 at $0.00 | filing |
| 18 Sep 2019filed 20 Sep 2019 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —138,659 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.